Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT

Author:

Feucht Judith1,Opherk Kathrin1,Lang Peter1,Kayser Simone1,Hartl Lena1,Bethge Wolfgang2,Matthes-Martin Susanne3,Bader Peter4,Albert Michael H.5,Maecker-Kolhoff Britta6,Greil Johann7,Einsele Hermann8,Schlegel Paul-Gerhardt9,Schuster Friedhelm R.10,Kremens Bernhard11,Rossig Claudia12,Gruhn Bernd13,Handgretinger Rupert1,Feuchtinger Tobias114

Affiliation:

1. Department of Pediatric Hematology/Oncology, University Children’s Hospital Tübingen, Tübingen, Germany;

2. Department of Hematology/Oncology, University Hospital Tübingen, Tübingen, Germany;

3. St. Anna Children’s Hospital Wien, Wien, Austria;

4. Department of Pediatric Hematology/Oncology, University Children’s Hospital Frankfurt, Frankfurt, Germany;

5. Department of Pediatric Hematology/Oncology, Dr. von Haunersches Kinderspital Munich, Munich, Germany;

6. Department of Pediatric Hematology/Oncology, Medizinische Hochschule Hannover, Hannover, Germany;

7. Department of Pediatric Oncology/Hematology, University Hospital Heidelberg, Heidelberg, Germany;

8. Department of Hematology, University Hospital Würzburg, Würzburg, Germany;

9. Department of Pediatric Hematology/Oncology, University Children’s Hospital Würzburg, Würzburg, Germany;

10. Clinic of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany;

11. Department of Pediatric Hematology/Oncology, University Children’s Hospital Essen, Essen, Germany;

12. Department of Pediatric Hematology and Oncology, University Children’s Hospital Münster, Münster, Germany;

13. Department of Pediatrics, Jena University Hospital, Jena, Germany; and

14. German Center for Infection Research, Ludwig Maximilians University Munich, Munich, Germany

Abstract

Key Points Adoptive transfer of TH-1 cells is a safe and effective treatment of refractory AdV infection after stem cell transplantation. AdV-related mortality was 9.5% in patients with a response to ACT (overall survival 71%) compared with 100% mortality in nonresponders.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 129 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3